Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

ReportsWorldwide has announced the addition of a new report title Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets to its growing collection of premium market research reports.

The cancer supportive care product market consists of drugs intended to prevent or treat the symptoms of cancer, and reduce the side effects of cancer treatments. Instead of extending a patient’s life expectancy, the emphasis is on improving overall quality of life. The key indications covered in this report are cancer pain, oral mucositis, chemotherapy-induced neutropenia (CIN), chemotherapy-induced anemia (CIA), chemotherapy-induced nausea and vomiting (CINV) and bone metastasis. As the number of people being diagnosed with cancer grows and access to effective treatment that allows patients to survive longer increases, demand for safe and effective cancer supportive care drugs will rise.

There are 245 products in active development in the cancer supportive care pipeline, but this includes products in development for smaller and less commercially significant indications. There are 169 products in active development for the key indication examined in this report, giving an average of 28 products per indication, the majority of which are at an early stage of development.

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=35933

Key topics covered in this report

The cancer supportive care market already contains some commercially successful products.

- Which classes of drug dominate the market?
- Which indication is the most commercially successful?
- How will commercially successful drugs perform over the forecast period?

The cancer supportive care pipeline is relatively small, but there is significant diversity in terms of molecule types and targets.

- Which molecular targets appear most frequently in the pipeline?
- What are the commercial prospects for the most promising late-stage pipeline products?

The cancer supportive care market is forecast to grow from $11.7 billion in 2015 to $12.4 billion in 2022, at a compound annual growth rate of 0.9%.

- Which products are forecast to drive growth?
- Will generic and biosimilar competition have a significant impact on the market over the forecast period?

The company landscape is becoming increasingly competitive.

- What are the leading companies in terms of market share?
- Which companies are forecast to experience the greatest growth in market share?
- What are the drivers of growth for key companies in the market?
- How dependent are the key companies on this disease cluster for revenue?

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/global-cancer-supportive-care-therapeutics-market-to-2022---patent-expirations-create-opportunities-for-biosimilars-in-the-chemotherapy-induced-anemia-and-neutropenia-markets

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.